Illumina's Next-Generation Sequencing (NGS) platforms are extensively utilised across research, clinical, and applied sectors. These systems produce large volumes of data that support diverse applications, including cancer research, genetic disease diagnostics, and agricultural biotechnology. Known for their high throughput, scalability, and rapid performance, this technology is a vital resource in contemporary genetic research and diagnostics.